CvWireless

CVRx is a commercial-stage medical device company focused on developing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. The company's flagship product, the Barostim System, is the first medical technology approved by the FDA to use neuromodulation—specifically baroreflex activation therapy—to improve symptoms in patients with heart failure with reduced ejection fraction. By electrically stimulating baroreceptors in the carotid sinus, the device triggers the body's natural blood flow regulation system to balance the autonomic nervous system. CVRx aims to provide a new standard of care for heart failure patients who remain symptomatic despite optimal medical therapy.